In Kentucky, we have focused specifically on the work of Dr. Suzanne Ildstad and her multi-disciplinary Institute for Cellular Therapeutics (ICT) at the University of Louisville. Dr. Ildstad is internationally recognized for her identification of a novel cell in bone marrow that makes it possible to safely transplant bone marrow stem cells from one person to another without life-threatening rejection, even when donor and recipient are not a genetic match. This “mini” bone marrow transplant builds a platform to permanently treat or cure autoimmune diseases and genetic blood disorders affecting many millions of people worldwide – and allows drug-free tolerance for transplanted organs and limbs. It is performed as an outpatient procedure. Total healthcare costs for patients suffering from these conditions are staggering; a significant portion of those costs will be eliminated when this treatment becomes standard of care. We believe, as do the U.S. Department of Defense and our strong academic partners, that the ICT is poised on the edge of research and clinical initiatives that will change the face and future of international healthcare.